SYDNEY, AUSTRALIA–(Marketwired – May 16, 2013) – Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN:US74154B2034) (“Prima”, the “Company”) has announced in pursuant to shareholder approval received at yesterday’s general meeting, the Company has today issued 13,287,500 fully paid ordinary shares (Shares) to its directors and 1,250,000 Shares to certain institutional investors on the same terms and price as the recently completed Share purchase … Read more
NEW YORK, May 16, 2013 (GLOBE NEWSWIRE) — NeoStem, Inc. (NYSE MKT:NBS) (“NeoStem” or the “Company”), a leader in the emerging cellular therapy market, today announced the geographic expansion of intellectual property protection around its lead product candidate, AMR-001, with the notice of patent grant in Malaysia (MY-147516-A) and notice of recommendation for patent allowance in the Philippines (1-2008-501074). These patents are in
LOS ANGELES–(BUSINESS WIRE)–ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a patent covering methods of use of interleukin 13-receptor alpha 2 protein (IL-13Rα2) in cancer immunotherapy. IL-13 is an immune regulatory cytokine and IL-13Rα2 is highly and specifically expressed in glioblastoma, ovarian and other solid tumors, but not in normal tissue. … Read more
LOS ANGELES–(BUSINESS WIRE)–Targeted Medical Pharma, Inc. (TRGM), a biotechnology company that develops and distributes prescription medical foods, convenience kits and generic pharmaceuticals to physicians and pharmacies, today announced financial results for its first quarter ended March 31, 2013. The Company posted record quarterly revenue of $2.811 million for the first … Read more
MINNEAPOLIS, May 15, 2013 /PRNewswire/ – BioDrain Medical, Inc. (BIOR) (the “Company”), producer of the FDA approved STREAMWAY™ System for automated, direct-to-drain surgical fluid disposal that reduces the risk of exposure to hazardous waste, today reported its results for the first quarter ended March 31, 2013.
- Revenues of $127,727 for
PRINCETON, N.J., May 15, 2013 /PRNewswire/ – Soligenix, Inc. (SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn’s … Read more
BLUE BELL, Pa., May 14, 2013 /PRNewswire/ – Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of Inovio’s SynCon® DNA vaccine against Ebola and Marburg filoviruses, labeled “Category A” bioterrorism agents by the U.S. government, the … Read more
NEW YORK, May 14, 2013 (GLOBE NEWSWIRE) — NeoStem, Inc. (NYSE MKT:NBS) (“NeoStem” or the “Company”), a leader in the emerging cellular therapy market, today announced that the Company and its subsidiary, Progenitor Cell Therapy (“PCT”), will present at multiple conferences in May.
8th Annual World Stem Cells and Regenerative Medicine Congress 2013
- Date and Time: Wednesday, May 22, 2:25 PM BST